Suchergebnisse

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Macy's (M), which belongs to the Zacks Retail -

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Williams-Sonoma (WSM), which belongs to the

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering CVS Health (CVS), which belongs to the Zacks

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Nvidia (NVDA), which belongs to the Zacks

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Applied Materials (AMAT), which belongs to the

T-Mobile US, Inc. TMUS delivered another solid quarterly performance, driven by healthy subscriber growth, expanding service revenues and improving profitability. Management also raised its adjusted

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Best Buy (BBY), which belongs to the Zacks

Archer Aviation Inc. ACHR is expected to report second-quarter 2026 results on Aug. 10, after market close.The Zacks Consensus Estimate for earnings is pegged at a loss of 25 cents per share

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Burlington Stores (BURL), which belongs to the

For Immediate Release

Chicago, IL – August 12, 2026 – Today, Zacks Equity Research discusses Aflac Inc. AFL, Globe Life GL, Trupanion TRUP and Employers Holdings, Inc. EIG.

Industry: Health

TransUnion TRU benefits from the rapidly growing big data and analytics market. A stable economic and lending environment, as well as well-executed acquisition and innovation strategies

Allogene Therapeutics ALLO incurred a second-quarter 2026 loss of 13 cents per share, narrower than the Zacks Consensus Estimate of a loss of 16 cents. Lower research and development (R&D) spending